Trial · NCT01552681
Results by group116
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 116
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Screening in Stimulated Whole Salivary Flow at Week 24 | Baminercept 100 mg | 0.0 | Standard Deviation 0.3 | mL/min | |
| Change From Screening in Stimulated Whole Salivary Flow at Week 24 | Placebo | 0.1 | Standard Deviation 0.2 | mL/min | |
| Change From Screening in Stimulated Whole Salivary Flow at Week 48 | Baminercept 100 mg | 0.0 | Standard Deviation 0.3 | mL/min | |
| Change From Screening in Stimulated Whole Salivary Flow at Week 48 | Placebo | -0.1 | Standard Deviation 0.2 | mL/min | |
| Change From Screening in Unstimulated Whole Salivary Flow at Week 24 | Baminercept 100 mg | 0.1 | Standard Deviation 0.2 | mL/min | |
| Change From Screening in Unstimulated Whole Salivary Flow at Week 24 | Placebo | 0.1 | Standard Deviation 0.1 | mL/min | |
| Change From Screening in Unstimulated Whole Salivary Flow at Week 48 | Baminercept 100 mg | 0.1 | Standard Deviation 0.1 | mL/min | |
| Change From Screening in Unstimulated Whole Salivary Flow at Week 48 | Placebo | 0.1 | Standard Deviation 0.1 | mL/min | |
| Change From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 24 | Baminercept 100 mg | -1.1 | Standard Deviation 2.3 | units on a scale | |
| Change From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 24 | Placebo | -0.4 | Standard Deviation 3.1 | units on a scale | |
| Percent of Subjects Classified as Responders According to the Patient Self-Assessment of Fatigue, Overall Dryness, and Joint Pain at Week 24 | Baminercept 100 mg | 20.7 | Percent of participants | ||
| Percent of Subjects Classified as Responders According to the Patient Self-Assessment of Fatigue, Overall Dryness, and Joint Pain at Week 24 | Placebo | 22.2 | Percent of participants | ||
| Percent of Subjects Classified as Responders According to the Patient Self-Assessment of Fatigue, Overall Dryness, and Joint Pain at Week 48 | Baminercept 100 mg | 21.4 | Percent of participants | ||
| Percent of Subjects Classified as Responders According to the Patient Self-Assessment of Fatigue, Overall Dryness, and Joint Pain at Week 48 | Placebo | 5.6 | Percent of participants | ||
| Change From Baseline in Visual Analog Scale (VAS) Scores for Sjogren's Syndrome Symptom Survey at Week 24 | Baminercept 100 mg | Difficulty speaking due to dryness | -0.7 | Standard Deviation 29.1 | mm |
| Change From Baseline in Visual Analog Scale (VAS) Scores for Sjogren's Syndrome Symptom Survey at Week 24 | Placebo | Difficulty speaking due to dryness | -9.2 | Standard Deviation 18.6 | mm |
| Change From Baseline in Visual Analog Scale (VAS) Scores for Sjogren's Syndrome Symptom Survey at Week 24 | Baminercept 100 mg | Difficulty swallowing due to dryness | -6.5 | Standard Deviation 23.6 | mm |
| Change From Baseline in Visual Analog Scale (VAS) Scores for Sjogren's Syndrome Symptom Survey at Week 24 | Placebo | Difficulty swallowing due to dryness | -10.1 | Standard Deviation 20.5 | mm |
| Change From Baseline in Visual Analog Scale (VAS) Scores for Sjogren's Syndrome Symptom Survey at Week 24 | Baminercept 100 mg | Dryness of mouth | -11.4 | Standard Deviation 27.2 | mm |
| Change From Baseline in Visual Analog Scale (VAS) Scores for Sjogren's Syndrome Symptom Survey at Week 24 | Placebo | Dryness of mouth | -12.7 | Standard Deviation 23.1 | mm |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01552681/results